Evidence map›Paper›PMID 28170005›Full record

ArticleTranslational psychiatry2017

Recurrence of depressive disorders after interferon-induced depression.

W-C Chiu, Y-P Su, K-P Su, P-C Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Obesity and Depression.Advances in experimental medicine and biology · 2026
    Review
  7. Review
  8. Review
  9. Neuroimmune modulation in liver pathophysiology.Journal of neuroinflammation · 2024
    Review
  10. Article
  11. How inflammation influences psychiatric disease.World journal of psychiatry · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Major depressive disorder.Nature reviews. Disease primers · 2023
    Review
  16. Intertwined associations between oxytocin, immune system and major depressive disorder.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Review
  17. Molecular basis and mechanism of action ofChinese herbal medicines · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

W-C ChiuDepartment of Psychiatry, Cathay General Hospital, Taipei, Taiwan.
Y-P SuDepartment of Psychiatry, Cathay General Hospital, Taipei, Taiwan.
K-P SuGraduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung, Taiwan.
P-C ChenInstitute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan.
Cathay General Hospital · TWChina Medical University Hospital · TWFu Jen Catholic University · TWNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon alpha (IFN-α)-treated patients commonly develop depression during the therapy period. Although most IFN-α-induced depressive disorders achieve remission after IFN-α therapy, no studies have examined the long-term mood effects of IFN-α treatment. We conducted a 12-year population-based cohort study of hepatitis C virus (HCV)-infected patients who were older than 20 years and had received IFN-α therapy. The sample was obtained from the Taiwan National Health Insurance Research Database. The cohort included patients with and without IFN-α-induced depression, matched randomly by age, sex and depression history, at a ratio of 1:10. The follow-up started after the last administration of IFN-α and was designed to determine the incidence of recurrent depressive disorder after IFN-α therapy. A total of 156 subjects were identified as having IFN-α-induced depression and achieving full remission after IFN-α therapy. The overall incidence of recurrent depressive disorders among patients with and without IFN-α-induced depression was 56.8 (95% confidence interval (CI), 42.4-76.1) and 4.1 (95% CI, 2.9-5.8) cases, respectively, per 100 000 person-years, P<0.001. The adjusted hazard ratios for recurrent depressive disorder were 13.5 (95% CI, 9.9-18.3) in the IFN-α-treated cohort and 22.2 (95% CI, 11.2-44.2) in the matched cohort for IFN-α-induced depression patients after adjusting for age, sex, income, urbanization and comorbid diseases. IFN-α-induced depression was associated with a high risk of recurrent depression. It was not a transient disease and might be considered an episode of depressive disorder. Continuation therapy might be considered, and further research is needed.

Indexed as

Antiviral AgentsCase-Control StudiesCohort StudiesDepressive DisorderFemaleHepatitis C, ChronicHumansIncidenceInterferon-alphaMajor Depressive DisorderMaleMiddle AgedProportional Hazards ModelsRecurrenceTaiwanAntiviral AgentsInterferon-alpha

Identifiers

PMID28170005
PMCPMC5438022
OpenAlexW2587531556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.